AK 1780
Alternative Names: AK-1780; AKP-23494954; RQ-00466479Latest Information Update: 28 Feb 2024
At a glance
- Originator RaQualia Pharma
- Class Analgesics
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuropathic pain
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Neuropathic-pain in unknown location (PO)
- 14 Jul 2023 Phase-II clinical trials in Neuropathic pain in USA (PO) (RaQualia Pharma pipeline, July 2023)
- 03 Feb 2021 Asahi Kasei Pharma completes a phase I trial in Pain in unknown location (PO)